MK-677 vs Ipamorelin
How they differ
- FDA status, the same for both (Not FDA-approved). MK-677: No FDA approval reported; on FDA’s compounding safety-risk list (category 2).1,2 Ipamorelin: Unapproved new drug in cited enforcement record.3
- Kinds of studies cited. MK-677: large randomized human trials. Ipamorelin: smaller controlled human trials. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | MK-677 | Ipamorelin |
|---|---|---|
| What it is | Not a peptide: a small molecule often looked up alongside peptides4,5 A synthetic small-molecule growth hormone secretagogue, recorded by FDA’s substance registry as ibutamoren mesylate and also called MK-677 and MK-0677.4,5 | A synthetic peptide of five amino acids, including unnatural ones, that acts as a ghrelin mimetic and stimulates growth hormone release.6 |
| FDA status | Not FDA-approved No FDA approval reported; on FDA’s compounding safety-risk list (category 2)1,2 No FDA approval is reported in the sources reviewed here. FDA lists ibutamoren mesylate in category 2 of both of its interim compounding policies, for substances that may present significant safety risks, and its advisory committee voted 13 to 1 in 2024 against adding it to the compounding list.1,2 | Not FDA-approved Unapproved new drug in cited enforcement record3 Not FDA-approved. FDA staff recommended in 2024 against adding either form to the 503A compounding list, and FDA lists ipamorelin acetate among compounding substances that may present significant safety risks under its 503B interim policy.1,6 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.7 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. MK-677 is not among them.7,8 | Not among the six peptides the policy lists.7 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Ipamorelin is not among them.7,8 |
| FDA compounding safety-risk page | Listed. FDA’s compounding safety-risk page, current as of April 22, 2026, lists ibutamoren mesylate in category 2 under both interim compounding policies: for pharmacies (section 503A) since September 29, 2023, and for outsourcing facilities (section 503B) since December 29, 2022.1 | Listed. FDA’s compounding safety-risk page, current as of April 22, 2026, lists ipamorelin acetate in category 2 under the 503B interim policy since September 29, 2023, and among substances whose nominations were withdrawn. It cites possible immune reactions and a published report of serious adverse events, including death.1 |
| Kinds of studies cited |
| Smaller controlled human trials
|
| Records collected | 2 ClinicalTrials.gov records and 14 PubMed records collected | |
| Area of study | ||
| Latest dated events |
|
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 3Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗
U.S. Department of Justice · Official source · Source checked July 22, 2026
- 4Ibutamoren mesylate (MK-677) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 5The nonpeptide growth hormone secretagogue, MK-0677, activates hypothalamic arcuate nucleus neurons in vivo (1998) · PMID 9535057 ↗
Journal of Neuroendocrinology · Official source · Source checked November 16, 2026
- 6FDA evaluation of ipamorelin-related bulk substances, August 19, 2024 ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026
- 7HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 8Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 9Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial (2008) · PMID 19015485 ↗
Neurology · Official source · Source checked November 16, 2026
- 10MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study (2011) · PMID 21067829 ↗
Archives of Gerontology and Geriatrics · Official source · Source checked November 16, 2026
- 11Federal Register notice 2024-21241 · published 2024-09-18 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List ↗
Federal Register via GovInfo · Official source · Source checked August 21, 2026